# Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab

> **NCT05188495** · — · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 60 (estimated)

## Conditions studied

- HER2-positive Metastatic Breast Cancer
- Previously Treated With Trastuzumab
- Trastuzumab Combined With Pertuzumab and Chemotherapy

## Interventions

- **DRUG:** trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy

## Key facts

- **NCT ID:** NCT05188495
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-10
- **Primary completion:** 2023-12-10
- **Final completion:** 2023-12-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188495, "Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05188495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*